Please ensure Javascript is enabled for purposes of website accessibility

Is Xoma Corporation A Buy?

By Todd Campbell - Mar 3, 2015 at 7:02AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Xoma Corporation could release late stage trial data that could significantly move the stock.

Source: Flickr user Ali T.

Clinical stage biotech stocks can have nausea-inspiring pops-and-drops tied to news, and that makes them suitable for only the most risk-tolerant of investors. However, investors willing to accept the risk of loss can reap substantial rewards if promising pipeline drugs like Xoma Corp's (XOMA -1.25%) gevokizumab succeed in clinical trials. Since Xoma could begin reporting late stage trial data for gevokizumab this year, let's take a closer look and see if its shares might be worth buying.

First, a bit of background
Gevokizumab is a monoclonal antibody that is being developed by Xoma and the large French drugmaker Servier.

The companies are evaluating the drug across a variety of eye-related diseases, but the most advanced studies are being conducted in rare patient populations, such as those with Behcet's disease.

Behcet's disease is an immune disease characterized by inflammation of the blood vessels, resulting in painful ulcers of the eye. Left unchecked, the disease can cause permanent vision loss in up to 20% of people who suffer from eye ulcers. Usually, that vision loss is because of damage to the optic nerve.

Source: Xoma Corporation

Currently, there are no clear-cut treatments for Behcet's disease. Instead, patients' symptoms are treated with steroids and immunosuppressants. In severe cases, AbbVie's autoimmune drug Humira or Johnson & Johnson's Remicade may be given.

The disease is not common in the U.S.; Xoma estimates that the disease affects between 5,000 and 7,500 Americans. Behcet's disease is, however, more common in countries along the Silk Road, from the Middle East to Asia. As a result, until recently, most of the research for gevokizumab in Behcet's has been undertaken by Servier in overseas markets. Servier's trial enrolled its targeted number of patients last year; however, delays in achieving the appropriate number of exacerbations have pushed back the release of data to 2015 (hopefully!).

Investors should also know that Xoma kicked off its own Behcet's disease study in the U.S. last year in order to build up enough data to support a possible future FDA filing.

Up to that point, Xoma's efforts had focused on the drug's use in non-infectious uveitis, or inflammation of the uvea in the eye. The company has two ongoing phase 3 studies in this indication. The first is evaluating the drug in patients after 56 days, and the second is evaluating patients after 168 days. The 56-day study's estimated completion date is in September 2015. The 168 day study's estimated completion date is in March 2015. Assuming that enrollment is going as planned and that the data are being collected at the pace predicted, those trial completion dates suggest that investors will soon have much clearer insight into gevokizumab's commercial opportunity.

Source: Xoma Corporation

By the numbers
One reason that investors are eagerly awaiting those clinical updates is because Xoma's spending has soared over the past couple years.

In the first nine months of 2014, the company's operating expenses totaled $77.2 million, up from $65.5 million the year before. As a result, the company reported an operating loss of $62.7 million for the nine month period, up from a loss of $42.6 million in the comparable period of 2013.

The spending caused Xoma's cash and equivalents to tumble from $101.7 million exiting 2013 to $54 million coming out of September. As a result, the company tapped the equity markets for a net $37.7 million in December, when it offered over 8 million in shares and accompanying warrants at price of $4.94 per share. The warrants have a per share conversion price of $7.90 and can be exercised at any point until they expire in two years.

The issuance gives the company a bit more financial flexibility to continue its research efforts and, if trial results are solid, prepare a filing for approval and for potential commercialization.

Looking ahead
Xoma has a lot riding on gevokizumab. If the drug fails to deliver in its late stage trials, it will cast significant doubt on the company's future. That means that investors need to keep a close eye on Xoma's press releases for trial details over the coming quarters. Since the company's expenses are so high, there's also the risk of additional dilution. Overall, while Xoma's an intriguing story, I think it's best to wait on the sidelines until we get more insight into how well gevokizumab performed in its trials and are given details on Xoma's timeline for any potential filing.


Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

XOMA Corporation Stock Quote
XOMA Corporation
$20.58 (-1.25%) $0.26
Johnson & Johnson Stock Quote
Johnson & Johnson
$170.20 (-0.53%) $0.91
Roche Holding AG Stock Quote
Roche Holding AG
$41.36 (0.49%) $0.20

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.